Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventyeight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7 9.3 years were included in this analysis

• Fecha de publicación: 2007
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/26225
• Acceso en línea: https://doi.org/10.1016/j.ophtha.2006.12.028; https://repository.urosario.edu.co/handle/10336/26225
• Palabra clave: Angiogenesis Inhibitors; Antibodies; Monoclonal; Antibodies; Monoclonal; Humanized; Bevacizumab; Diabetic Retinopathy; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Injections; Macular Edema; Male; Middle Aged; Ophthalmoscopy; Retrospective Studies; Tomography; Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body
• License: Restringido (Acceso a grupos específicos)